Evidence map›Paper›PMID 29422776›Full record

ArticleCancer cell international2018

Different TP53 mutants in p53 overexpressed epithelial ovarian carcinoma can be associated both with altered and unaltered glycolytic and apoptotic profiles.

Stephanie Antoun, David Atallah, Roula Tahtouh, Nada Alaaeddine, Malak Moubarak, Abir Khaddage, Eliane Nasr Ayoub, George Chahine, George Hilal

Open access · goldAbstract read
In one paragraph

Article in Cancer cell international, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 15 citations in OpenAlex.

  1. The multifunctional proline-rich domain of p53 tumor suppressor.Biochimica et biophysica acta. Reviews on cancer · 2025
    Review
  2. Comprehensive bioinformatics analysis of co-mutation ofTranslational cancer research · 2025
    Article
  3. Review
  4. Interplay between altered metabolism and DNA damage and repair in ovarian cancer.BioEssays : news and reviews in molecular, cellular and developmental biology · 2024
    Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. BioMed research international · 2020
    Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Stephanie Antoun1Cancer and Metabolism Laboratory, Faculty of Medicine, Saint Joseph University, Damascus Road, Riad el Solh, Beirut, 1107 2180 Lebanon.
David Atallah2Obstetrics and Gynecology Department, Hotel-Dieu De France Hospital, Beirut, Lebanon.
Roula Tahtouh1Cancer and Metabolism Laboratory, Faculty of Medicine, Saint Joseph University, Damascus Road, Riad el Solh, Beirut, 1107 2180 Lebanon.
Nada Alaaeddine3Regenerative Medicine and Inflammation Laboratory, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon.
Malak Moubarak2Obstetrics and Gynecology Department, Hotel-Dieu De France Hospital, Beirut, Lebanon.
Abir Khaddage4Anatomy and Pathology Department, Hotel-Dieu De France Hospital, Beirut, Lebanon.
Eliane Nasr Ayoub5Anesthesiology Department, Hotel-Dieu De France Hospital, Beirut, Lebanon.
George Chahine6Oncology Department, Hotel-Dieu De France Hospital, Beirut, Lebanon.
George Hilal1Cancer and Metabolism Laboratory, Faculty of Medicine, Saint Joseph University, Damascus Road, Riad el Solh, Beirut, 1107 2180 Lebanon.
Hôtel-Dieu de France · LBSaint Joseph University · LB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundp53 is a tumor suppressor and key regulator of glycolysis in cancer cells, however highly mutated in tumors. In ovarian cancer, studies concerning p53 mutations focus on the DNA binding domain since the majority of hotspot mutations affects this region. Yet, mutations in other regions such as the proline rich domain may also affect the protein's expression and activity. The aim of this study is to investigate the effect of various positions of mutations in TP53 gene on glycolysis, apoptosis and transcription of p53 target genes.

methodsMutations frequency and their effect on p53 expression were assessed by PCR-SSCP, sequencing and immunohistochemistry on 30 ovarian cancer biopsies. Six tumors were cultured, as well as SK-OV-3, OVCAR-3 and Igrov-1. SK-OV-3 cells were transfected with 2 TP53 mutants. p53 transcriptional activity was assayed by qPCR, apoptosis by flow cytometry and glycolysis by glucose and lactate measurements, with quantification of glycolytic enzymes expression.

resultsOur results showed a high frequency of the P72R mutant, associated with p53 overexpression in the ovarian biopsies. However, P72R mutant cells showed similar apoptosis and glycolysis as WT cells. DNA binding domain mutations decreased the transcriptional activity of the protein and increased glucose consumption and lactate production.

conclusionDespite the overexpression of the P72R mutated protein in the biopsies, it showed a similar apoptotic activity and glucose regulation ability as WT p53. Knowing that p53 expression status is used for chemotherapeutic approaches and prognosis in ovarian cancer, the results obtained highlight the importance of locating TP53 mutations.

Indexed as

ApoptosisGlucose metabolismMutationOvarian cancerp53 overexpression

Identifiers

PMID29422776
PMCPMC5791177
OpenAlexW2796452348

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.